Semaglutide Mechanism of Action: GLP-1 Receptor Agonism in Research

Semaglutide is a selective GLP-1 receptor agonist and the reference standard in the incretin research class. Its 94% sequence homology to native human GLP-1, combined with two structural modifications, is what makes it a workhorse compound in metabolic laboratories.

The two structural modifications

Modification	Effect
Aib substitution at position 8	Resists DPP-4 cleavage → longer activity in assays
C18 fatty-acid chain	Strong albumin binding → extended plasma half-life

Native GLP-1 has a plasma half-life of minutes — it is degraded by DPP-4 almost immediately. Semaglutide’s Aib-8 residue blocks that degradation, and the C18 diacid chain anchors the peptide to albumin, giving it a circulation time suitable for once-weekly dosing in the clinic.

Receptor selectivity matters

Semaglutide activates only the GLP-1 receptor. That selectivity is what makes it the clean reference for GLP-1-specific effects:

• GLP-1 selective → isolates the GLP-1 pathway in receptor-binding and signaling studies
• Tirzepatide (dual GIP/GLP-1) and retatrutide (triple GIP/GLP-1/glucagon) add receptors on top of the same incretin base

For dose-response and receptor-pharmacology comparisons, running semaglutide alongside the multi-agonist compounds separates the GLP-1 contribution from the additional receptor arms.

Research applications

Semaglutide is used as a reference standard in:

• GLP-1 receptor binding assays
• Insulinotropic and β-cell signaling research
• Appetite and food-intake pathway studies
• Formulation-stability testing (its albumin-binding design is itself a study subject)

Reference data

CAS 910463-68-2 · C187H291N45O59 · MW 4113.6 · 5 mg lyophilized vial · 99.4% purity

Reconstitute with bacteriostatic water — see semaglutide titration math and the reconstitution calculator. Compare with tirzepatide and retatrutide.